[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-372352-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-372352-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","malignant-ascites-in-ovarian-cancer-is-compatible-with-long-term-10-year-survival-with-associations-to-clinicopathological-features","Malignant ascites in ovarian cancer is compatible with long-term (10 year) survival with associations to clinicopathological features","","Objectives: Ovarian cancer may present with malignant ascites at diagnosis or recurrence, and although advanced, reported prognosis can be favorable. This retrospective study details survival outcomes, especially long-term (10-year) survival, and identifies predictive clinicopathological factors. Methods: Malignant ascites cases confirmed by cytology with radiologic/histologic ovarian primary evidence over three decades were reviewed, assessing demographic, clinical, biochemical, hematological, serological, and pathological data for survival analysis. Results: 277 cases showed mean overall survival of 69.3 months; 27 (9.7%) were long survivors. Older age, high-grade histology, low hemoglobin/albumin/total protein, prolonged APTT, ECOG ≥3, and prior chemotherapy related to worse survival, while chemotherapy after ascites onset related to better outcome. APTT, ECOG, total protein, and prior chemotherapy remained independent predictors. Remission was common among long survivors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/malignant-ascites-in-ovarian-cancer-is-compatible-with-long-term-10-year-survival-with-associations-to-clinicopathological-features/372352/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/malignant-ascites-in-ovarian-cancer-is-compatible-with-long-term-10-year-survival-with-associations-to-clinicopathological-features/372352.png","ImageObject",300,407,{"name":42,"@type":43},"\tCallum ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient proportion achieved long-term (10-year) survival in ovarian cancer with malignant ascites?","Question",{"text":63,"@type":64},"Among 277 reviewed cases, 27 patients (9.7%) achieved long-term survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which baseline factors were associated with higher mortality and shorter overall survival?",{"text":68,"@type":64},"Old age, high-grade histology, low hemoglobin, low serum albumin and total protein, long APTT, ECOG score ≥3, and prior chemotherapy were linked to worse outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"How did treatment after onset of malignant ascites affect survival?",{"text":72,"@type":64},"Administration of chemotherapy after ascites onset correlated with better outcomes, and patients receiving surgical treatment after ascites were more likely to experience long survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},372352,1790497783,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","Chow et al. Journal of Ovarian Research (2025) 18:98 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-025-01657-8](https://doi.org/10.1186/s13048-025-01657-8)  \nRESEARCH Open Access  \nMalignant ascites in ovarian cancer is  compatible with long-term (10 year) survival with associations to clinicopathological features  \nLok Hang Chow 1, Annabelle M. Y. Ngai 1, Cheuk-yin Tang 1, Jacqueline H. S. Lee2, Alfred L. H. Lee3, Joshua J. X. Li4* and Philip P. C. Ip4  \nAbstract  \nObjectives Ovarian cancer can present with malignant ascites at initial diagnosis or disease recurrence. Although indicative of advanced disease, the prognosis of malignant ascites is reported to be favorable for ovarian cancers compared to other malignancies. This study aims to detail the survival, in particular long-term (10 year), and predictive clinicopathological factors.  \nMethods Cases of malignant ascites confirmed by cytology and radiologic/histologic evidence supportive of ovarian primary, over three-decades, were retrieved. Survival data was obtained, and long-term survivors were identified. Corresponding demographical, clinical, biochemical, hematological, serological, and pathological data at onset of ascites were reviewed for survival analysis.  \nResults Totally 277 cases were reviewed, with a mean overall survival of 69.3 months, including 27 (9 . 7%) long survivors. Old age, high-grade histology, low haemoglobin, serum albumin and total protein, long APTT, ECOG score ≥ 3 and prior chemotherapy associated with mortality and shorter overall survival (p = 0 . 03-\u003C0 . 01), whereas administration of chemotherapy after onset of ascites correlated with better outcome (p \u003C 0. 01) . APTT, ECOG score, total serum protein and prior chemotherapy remained independent predictors on multivariable analysis. Remission was common in long survivors, with only one (3 . 7%) patient dying of disease. Long survival was more common inpatients with younger age, low-grade serous and endometrioid histology, lower platelet count, higher serum albumin and total protein, and patients receiving surgical treatment after ascites (p \u003C 0. 05) .  \nConclusion Factors predicting long survival in ovarian carcinoma patients with malignant ascites were age, histology, hematological and biochemical markers, and those with favorable clinicopathological features are compatible with long survival.  \nKeywords Malignant Ascites, Long survivor, Ovarian cancer  \n*Correspondence: Joshua J. X. Li joshuali@hku.hk  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nChow et al. Journal of Ovarian Research (2025) 18:98  \nSynopsis  \nNearly 10% of patients achieved 10-year long survival with malignant ascites in ovarian cancer, and is correlated with age, histology, treatment and serological parameters.  \nWhat does this study adds to the clinical work  \nAverage overall survival after onset of malignant as","cbCaicZoa1iWnpjd","https://ap.wps.com/l/cbCaicZoa1iWnpjd","pdf",1301717,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusion\n# Synopsis\n# Introduction\n# Methodology","[{\"question\":\"What patient proportion achieved long-term (10-year) survival in ovarian cancer with malignant ascites?\",\"answer\":\"Among 277 reviewed cases, 27 patients (9.7%) achieved long-term survival.\"},{\"question\":\"Which baseline factors were associated with higher mortality and shorter overall survival?\",\"answer\":\"Old age, high-grade histology, low hemoglobin, low serum albumin and total protein, long APTT, ECOG score ≥3, and prior chemotherapy were linked to worse outcomes.\"},{\"question\":\"How did treatment after onset of malignant ascites affect survival?\",\"answer\":\"Administration of chemotherapy after ascites onset correlated with better outcomes, and patients receiving surgical treatment after ascites were more likely to experience long survival.\"}]","Malignant ascites in ovarian cancer is compatible with long-term (10 year) survival with associations to clinicopathological features | PDF",1790194317,23]